Study finds no overall survival benefit, but improved quality of life with talazoparib in BRCA-mutated breast cancer
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) ...
Apr 27, 2020
0
1